TERRASCEND CORP (TSND.CA) Stock Fundamental Analysis
TSX:TSND - Toronto Stock Exchange - CA88105E1088 - Common Stock - Currency: CAD
Overall TSND gets a fundamental rating of 3 out of 10. We evaluated TSND against 33 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TSND have multiple concerns. TSND is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TSND had negative earnings in the past year.
TSND had a positive operating cash flow in the past year.
TSND had negative earnings in 4 of the past 5 years.
In multiple years TSND reported negative operating cash flow during the last 5 years.
1.2 Ratios
TSND has a Return On Assets of -12.78%. This is in the lower half of the industry: TSND underperforms 60.61% of its industry peers.
TSND has a Return On Equity of -46.60%. This is in the lower half of the industry: TSND underperforms 66.67% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.95%, TSND belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.78% | ||
| ROE | -46.6% | ||
| ROIC | 3.95% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 9.68%, TSND belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
TSND's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 49.84%, TSND is in the better half of the industry, outperforming 75.76% of the companies in the same industry.
In the last couple of years the Gross Margin of TSND has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.68% | ||
| PM (TTM) | N/A | ||
| GM | 49.84% |
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
2. Health
2.1 Basic Checks
TSND has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
TSND has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TSND has been increased compared to 5 years ago.
Compared to 1 year ago, TSND has a worse debt to assets ratio.
2.2 Solvency
TSND has an Altman-Z score of -0.95. This is a bad value and indicates that TSND is not financially healthy and even has some risk of bankruptcy.
TSND has a Altman-Z score (-0.95) which is in line with its industry peers.
TSND has a debt to FCF ratio of 9.20. This is a negative value and a sign of low solvency as TSND would need 9.20 years to pay back of all of its debts.
TSND has a Debt to FCF ratio of 9.20. This is in the better half of the industry: TSND outperforms 69.70% of its industry peers.
TSND has a Debt/Equity ratio of 1.17. This is a high value indicating a heavy dependency on external financing.
TSND has a worse Debt to Equity ratio (1.17) than 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 9.2 | ||
| Altman-Z | -0.95 |
ROIC/WACC0.37
WACC10.67%
2.3 Liquidity
A Current Ratio of 1.31 indicates that TSND should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.31, TSND is doing worse than 63.64% of the companies in the same industry.
A Quick Ratio of 0.70 indicates that TSND may have some problems paying its short term obligations.
With a Quick ratio value of 0.70, TSND is not doing good in the industry: 69.70% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
TSND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.
Looking at the last year, TSND shows a decrease in Revenue. The Revenue has decreased by -9.59% in the last year.
Measured over the past years, TSND shows a very strong growth in Revenue. The Revenue has been growing by 36.80% on average per year.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-9.59%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-11.95%
3.2 Future
Based on estimates for the next years, TSND will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.08% on average per year.
TSND is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.56% yearly.
EPS Next Y61.47%
EPS Next 2Y28.11%
EPS Next 3Y20.17%
EPS Next 5Y13.08%
Revenue Next Year-2%
Revenue Next 2Y0.26%
Revenue Next 3Y4.51%
Revenue Next 5Y4.56%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TSND. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSND. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TSND's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TSND is cheaper than 90.91% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TSND is valued cheaper than 90.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.55 | ||
| EV/EBITDA | 6.11 |
4.3 Compensation for Growth
TSND's earnings are expected to grow with 20.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.11%
EPS Next 3Y20.17%
5. Dividend
5.1 Amount
No dividends for TSND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TSND (7/25/2025, 7:00:00 PM)
0.61
+0.08 (+15.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners42.98%
Inst Owner ChangeN/A
Ins Owners3.71%
Ins Owner ChangeN/A
Market Cap225.70M
Analysts82.22
Price Target2.12 (247.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.07%
Min EPS beat(2)-259.48%
Max EPS beat(2)-20.66%
EPS beat(4)0
Avg EPS beat(4)-94.6%
Min EPS beat(4)-259.48%
Max EPS beat(4)-17.65%
EPS beat(8)0
Avg EPS beat(8)-198.29%
EPS beat(12)2
Avg EPS beat(12)-301.75%
EPS beat(16)3
Avg EPS beat(16)-238.41%
Revenue beat(2)0
Avg Revenue beat(2)-2.93%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)-2.6%
Revenue beat(4)0
Avg Revenue beat(4)-4.32%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)-2.6%
Revenue beat(8)2
Avg Revenue beat(8)-2.44%
Revenue beat(12)2
Avg Revenue beat(12)-4.47%
Revenue beat(16)2
Avg Revenue beat(16)-6.51%
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.1%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-1.55%
Revenue NQ rev (3m)-3.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.56 | ||
| P/FCF | 7.55 | ||
| P/OCF | 5.07 | ||
| P/B | 1.01 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.11 |
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.08
FCFY13.25%
OCF(TTM)0.12
OCFY19.73%
SpS1.09
BVpS0.61
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.78% | ||
| ROE | -46.6% | ||
| ROCE | 5.49% | ||
| ROIC | 3.95% | ||
| ROICexc | 4.2% | ||
| ROICexgc | 9.48% | ||
| OM | 9.68% | ||
| PM (TTM) | N/A | ||
| GM | 49.84% | ||
| FCFM | 7.39% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-2.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y1.66%
ROICexc growth 5YN/A
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 9.2 | ||
| Debt/EBITDA | 3.75 | ||
| Cap/Depr | 47.22% | ||
| Cap/Sales | 3.62% | ||
| Interest Coverage | 1.2 | ||
| Cash Conversion | 63.51% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | -0.95 |
F-Score5
WACC10.67%
ROIC/WACC0.37
Cap/Depr(3y)90.87%
Cap/Depr(5y)192.32%
Cap/Sales(3y)7.77%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y61.47%
EPS Next 2Y28.11%
EPS Next 3Y20.17%
EPS Next 5Y13.08%
Revenue 1Y (TTM)-9.59%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-11.95%
Revenue Next Year-2%
Revenue Next 2Y0.26%
Revenue Next 3Y4.51%
Revenue Next 5Y4.56%
EBIT growth 1Y-27.13%
EBIT growth 3Y6.79%
EBIT growth 5YN/A
EBIT Next Year153.22%
EBIT Next 3Y48.84%
EBIT Next 5Y33.62%
FCF growth 1Y156.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2719.22%
OCF growth 3YN/A
OCF growth 5YN/A